Abstract

The majority of patients who are diagnosed with Hodgkin lymphoma (HL) will be cured with primary chemotherapy. For those who relapse, autologous stem cell transplantation (ASCT) has become the standard of care. Randomized clinical trials have demonstrated that approximately 50% of patients with chemosensitive relapsed HL can achieve long term disease free survival with ASCT. However, optimal therapy of those who have chemorefractory disease or who relapse after an ASCT has not been established. Reduced intensity allogeneic stem cell transplantation may benefit these patients, although a definite graft versus HL effect has not been demonstrated and treatment-related mortality remains relatively high. New salvage regimens that incorporate gemcitabine, vinorelbine, rituximab, and/or monoclonal antibodies against CD30 are being investigated.

Original languageEnglish
Pages (from-to)233-243
Number of pages11
JournalBlood Reviews
Volume21
Issue number5
DOIs
StatePublished - Sep 1 2007

Keywords

  • Allogeneic stem cell transplantation
  • Autologous stem cell transplantation
  • Hodgkin lymphoma
  • Salvage therapy

Fingerprint Dive into the research topics of 'Therapy of Relapsed Hodgkin Lymphoma'. Together they form a unique fingerprint.

  • Cite this